MedTech logo
 
 
 
 
 
 
temp_image_2

t: 0161 820 8440

e:  

News

Wellcome Boost for a MedTECH Centre Company

The ability to swallow is something most people take for granted but is actually one of the most complex neuromuscular interactions in the human body that involves around 50 pairs of muscles and many nerves. Unfortunately the ability to swallow can be lost following strokes.

 

Around 150,000 people suffer stroke in England alone and studies have shown that over a quarter of these will have some difficulty swallowing. Loss of swallowing function can have serious consequences such as coughing and choking, which can lead to aspiration pneumonia.

 

Phagenesis has developed the world's first clinically-proven device to treat dysphagia in stroke patients in the first few weeks while they are hospitalised. With the help of the Wellcome Trust, Phagenesis is now developing and testing a new version of its device to treat patients suffering from long-term dysphagia.

 

Daniel Green, CEO of Phagenesis, said: "Our technology can make a significant difference to patients in the hospital who have this difficult-to-treat condition. We believe this benefit can be extended more widely to people outside the hospital setting. We are delighted to have the support of the Wellcome Trust to adapt our technology and reach these patients and improve their quality of life."

 

Phagenesis were the first company to take space in the MedTECH Centre in 2010 and have seen accelerating growth through a series of funding rounds.

Daniel Green

Daniel Green

back to news listing

Supported by:


Central Manchester University Hospitals logoManchester Science Parks logoTrusTECH logo